Merck & Co. is putting down $30 million upfront to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma (GBM).

Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal ...

As the FDA's Commissioner's National Priority Voucher (CNPV) program has picked up steam, with 15 companies now having ...

ARPA-H is seeking proposals from experts in surgery, imaging and AI, including academic and scientific research institutions ...

A drug safety group has delivered a positive analysis for a Sarepta Therapeutics-licensed RNA medicine, with the same study ...

VC Versant Ventures is unveiling Dayra Therapeutics, a new biotech working on oral macrocyclic peptide drugs—a mission that ...

Abbott has launched an effort to replace some of its FreeStyle Libre 3 continuous glucose monitors—following reports of ...

Johnson & Johnson is paying $3.05 billion to acquire Halda Therapeutics, obtaining a novel cell death platform while ...

AbbVie is opening submissions for an award that will provide one Canadian biotech with free access to lab space and executive ...

The Federal Trade Commission (FTC) has begun outlining its case against Edwards Lifesciences' proposed purchase of heart ...

Most AI drug development is fueled by foundation models in biology—models that are trained on vast biological data sets and ...

Swedish biotech Sprint Bioscience is selling off an early-stage TREX1 cancer program to Gilead for $14 million upfront, plus ...